| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Location /Country | Title | Interventions | Sponsor/Collaborators | Phases | Enrollment target | Start date | Comment | Direct link | ||||||||||||||||||||
2 | Egypt | Efficacy of Faviprevir in COVID-19 Treatment | Drug: Favipiravir Drug: Placebos | Tanta University | Phase 2|Phase 3 | 40 | 17-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04351295?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=1 | |||||||||||||||||||||
3 | Egypt | Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19 | Drug: ACEIs Drug: Conventional treatment | Tanta University | Phase 3 | 60 | 15-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04345406?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=2 | |||||||||||||||||||||
4 | Egypt | A Real-life Experience on Treatment of Patients With COVID 19 | Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide | Tanta University | Phase 2|Phase 3 | 100 | 15-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04345419?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=3 | |||||||||||||||||||||
5 | Egypt | The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment | Drug: Chloroquine Drug: Nitazoxanide Drug: Ivermectin | Tanta University | Phase 2|Phase 3 | 60 | 17-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04351347?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=4 | |||||||||||||||||||||
6 | Egypt | Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus | Dietary Supplement: Natural Honey Other: Standard Care | Misr University for Science and Technology | Phase 3 | 1000 | March 25, 2020 | https://clinicaltrials.gov/ct2/show/NCT04323345?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=5 | |||||||||||||||||||||
7 | Egypt | Administration of Chloropromazine as a Treatment for COVID-19 | Drug: Chlorpromazine Injection | Cairo University | Phase 1|Phase 2 | 60 | 1-May-2020 | https://clinicaltrials.gov/ct2/show/NCT04354805?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=5 | |||||||||||||||||||||
8 | Egypt | PRA-001 Plasma Rich Antibodies From Recovered Patients From COVID19 | Other: Antibody-Rich Plasma from COVID-19 recovered patients | Ain Shams University | Not Applicable | 20 | 20-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04348877?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=6 | |||||||||||||||||||||
9 | Egypt | FAV-001 Efficacy and Safety of Favipiravir in Management of COVID-19 | Drug: favipiravir|Drug: Standard of care therapy | Ain Shams University | Phase 3 | 100 | 20-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04349241?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=7 | |||||||||||||||||||||
10 | Egypt | Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 | Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine | Ain Shams University | Phase 3 | 100 | 20-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04360122?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=8 | |||||||||||||||||||||
11 | Egypt | Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19 | Biological: intradermal injection of BCG Vaccine|Other: placebo | Ain Shams University | Phase 3 | 900 | 20-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04350931?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=9 | |||||||||||||||||||||
12 | Egypt | Efficacy of Chloroquine in COVID-19 Treatment | Drug: Chloroquine | Tanta University | Phase 2|Phase 3 | 40 | 17-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04353336?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=10 | |||||||||||||||||||||
13 | Egypt | Isotretinoin Assessment the Activity Value of 13- Cis-Retinoic Acid(Isotretinoin) in the Treatment of COVID-19 | Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Standard treatment | Kafrelsheikh University | Phase 3 | 45 | 1-Apr-2020 | https://clinicaltrials.gov/ct2/show/NCT04353180?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=11 | |||||||||||||||||||||
14 | Egypt | MV-COVID19 Measles Vaccine in HCW | Drug: Measles-Mumps-Rubella Vaccine | Kasr El Aini Hospital | Phase 3 | 200 | 1-May-2020 | https://clinicaltrials.gov/ct2/show/NCT04357028?type=Intr&cond=covid&map_cntry=EG&draw=2&rank=12 https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953 | |||||||||||||||||||||
15 | Egypt | Management of Covid-19 Patients During Home Isolation | Device: Oxygen Therapy|Procedure: Physical Therapy | Cairo University | Not Applicable | 60 | March 15, 2020 | https://ClinicalTrials.gov/show/NCT04368923 | |||||||||||||||||||||
16 | Egypt | COVID-19 Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 | Biological: exchange blood transfusion from normal donor Biological: plasma from convalescent patients with COVID-19 Drug: Methylene Blue 5 MG/ML | Ain Shams University | Phase 2 | 15 | 5-May-2020 | https://ClinicalTrials.gov/show/NCT04376788 | |||||||||||||||||||||
17 | Egypt | Inhalable Sodium Bicarbonate: A Possible Adjuvant Treatment of Patients With Novel COVID-19 | Drug: Sodium Bicarbonate | Mansoura University | Early Phase 1 | 20 | 1-Apr-2020 | https://ClinicalTrials.gov/show/NCT04374591 | |||||||||||||||||||||
18 | Egypt | COVID-19 Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement | Other: implementing Online Distance Learning | Kasr El Aini Hospital | Not Applicable | 180 | 1-Feb-2020 | https://ClinicalTrials.gov/show/NCT04372693 | |||||||||||||||||||||
19 | Egypt | SnPPIX Efficacy of Sn-protoporphyrin IX (SnPPIX) and Sulfonatoporphyrin(TPPS)Against Covid-19 | Drug: SnPP Protoporphyrin Drug: Sulfonatoporphyrin(TPPS) | Kafrelsheikh University | Phase 1 | 56 | 1-May-2020 | https://ClinicalTrials.gov/show/NCT04371822 | |||||||||||||||||||||
20 | Egypt | SCOPE Silymarin in COVID-19 Pneumonia | Drug: Silymarin|Drug: Placebo | Cairo University | Phase 3 | 50 | June 1, 2020 | https://ClinicalTrials.gov/show/NCT04394208 | |||||||||||||||||||||
21 | Egypt | New Antiviral Drugs for Treatment of COVID-19 | Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : | Mansoura University | Phase 3 | 100 | May 2020 | https://ClinicalTrials.gov/show/NCT04392427 | |||||||||||||||||||||
22 | Egypt | Ivermectin and Doxycycine in COVID-19 Treatment | Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine | Tanta University | Phase 2|Phase 3 | 40 | June 1, 2020 | https://ClinicalTrials.gov/show/NCT04403555 | |||||||||||||||||||||
23 | Egypt | Using PRP and Cord Blood in Treatment of Covid -19 | Combination Product: stem cells | Aljazeera Hospital | Not Applicable | 100 | 25-May-2020 | https://ClinicalTrials.gov/show/NCT04393415 | |||||||||||||||||||||
24 | Egypt | Folic acid: A new suggested prevention and treatment of COVID-19 infection | Drug: folic acid|Other: standard care | Faculty of Medicine Cairo university | Phase 2 | 60 | 20-Apr-2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10971 | |||||||||||||||||||||
25 | Egypt | COVID-19_LF Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease | Dietary Supplement: Lactoferrin (Apolactoferrin) Drug: Placebo of excipient(s) will be administered | National Research Center, Egypt Egyptian Military Medical Services | Phase 2 | 516 | June 1, 2020 | https://ClinicalTrials.gov/show/NCT04412395 | |||||||||||||||||||||
26 | Egypt | Using PRP and Cord Blood in Treatment of Covid -19 | Combination Product: stem cells | Aljazeera Hospital | Not Applicable | 100 | 25-May-2020 | https://ClinicalTrials.gov/show/NCT04393415 | |||||||||||||||||||||
27 | Egypt | Ivermectin in Treatment of COVID-19 | Drug: Ivermectin | Zagazig University | Phase 2|Phase 3 | 100 | May 31, 2020 | https://ClinicalTrials.gov/show/NCT04445311 | |||||||||||||||||||||
28 | Egypt | Prophylactic Ivermectin in COVID-19 Contacts | Drug: Ivermectin Tablets | Zagazig University | Phase 2|Phase 3 | 100 | May 31, 2020 | Completed | https://ClinicalTrials.gov/show/NCT04422561 | ||||||||||||||||||||
29 | Egypt | Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients | Drug: Pentoxifylline|Drug: Placebo | Sadat City University | Phase 1|Phase 2 | 200 | June 13, 2020 | https://ClinicalTrials.gov/show/NCT04433988 | |||||||||||||||||||||
30 | Egypt | Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19 | Drug: Chloroquine|Drug: zinc | Tanta University | Phase 3 | 200 | June 23, 2020 | https://ClinicalTrials.gov/show/NCT04447534 | |||||||||||||||||||||
31 | Egypt | Ivermectin In Treatment of COVID 19 Patients | Drug: Ivermectin | Ministry of Health and Population, Egypt | Not Applicable | 100 | June 9, 2020 | https://ClinicalTrials.gov/show/NCT04425707 | |||||||||||||||||||||
32 | Egypt | Efficacy and Safety of Sirolimus in COVID-19 Infection | Drug: Sirolimus | Alexandria University | Phase 2 | 40 | 25-Jul-2020 | https://ClinicalTrials.gov/show/NCT04461340 | |||||||||||||||||||||
33 | Egypt | Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 | Drug: sofosbuvir Drug: Ribavirin | Tanta University | Phase 2|Phase 3 | 60 | 1-Aug-2020 | https://ClinicalTrials.gov/show/NCT04460443 | |||||||||||||||||||||
34 | Egypt | CP IN COVID19 Use of Convalescent Plasma for Treatment of Patients With COVID-19 Infection | Drug: Convalescent Plasma | Cairo University | Phase 1|Phase 2 | 60 | June 2020 | https://ClinicalTrials.gov/show/NCT04438694 | |||||||||||||||||||||
35 | Egypt | Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19 | Procedure: Therapeutic Plasma Exchange (TPE) | Alexandria University | Not Applicable | 10 | 20-July-2020 | https://ClinicalTrials.gov/show/NCT04457349 | |||||||||||||||||||||
36 | Egypt | Corticosteroid Nasal Spray in COVID-19 Anosmia | Drug: momentasone furatenasal spray | Benha University | Phase 3 | 50 | August 1, 2020 | https://ClinicalTrials.gov/show/NCT04484493 | |||||||||||||||||||||
37 | Egypt | Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19 | Drug: inhalable hydroxychloroquine (HCQ)|Drug: supportive and symptomatic treatment | Mansoura University | Not Applicable | 40 | 15-Jul-2020 | https://ClinicalTrials.gov/show/NCT04477083 | |||||||||||||||||||||
38 | Egypt | Digital vs Analog Impression in Cases of All-on-4 - Prosthesis | Other: DIG Axial|Other: DIG Tilted|Other: CIG Axial|Other: CIG Tilted | October University for Modern Sciences and Arts | Not Applicable | 56 | 11-Jul-2018 | https://ClinicalTrials.gov/show/NCT04475913 | |||||||||||||||||||||
39 | Egypt | Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients | Drug: Sofosbuvir|Drug: Daclatasvir|Drug: Ribavirin|Drug: Ledipasvir | Tanta University | Phase 2|Phase 3 | 200 | 1-Jul-2020 | https://ClinicalTrials.gov/show/NCT04497649 | |||||||||||||||||||||
40 | Egypt | Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19 | Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide | Assiut University|Helwan University | Phase 4 | 240 | 15-July-2020 | https://ClinicalTrials.gov/show/NCT04498936 | |||||||||||||||||||||
41 | Egypt | Toclizumam Versus Dexamethasone in Severe Covid19 Cases | Drug: Tocilizumab | South Valley University | Not Applicable | 69 | March 2020 | https://ClinicalTrials.gov/show/NCT04519385 | |||||||||||||||||||||
42 | Egypt | Nebulized heparin in patients with mainly moderate coronavirus disease 2019: Randomized controlled trial. COVID-19 | Drug:Standard of care plus nebulized heparin Other: Standard of care | Dr Tarek Ismail | Not Available | 100 | June 15, 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12158 | |||||||||||||||||||||
43 | Ghana | PROTECT Sur Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 | Drug: Hydroxychloroquine Drug: Lopinavir/Ritonavir Drug: Hydroxychloroquine + Lopinavir/Ritonavir Drug: standard of care | National Institute of Health Research, UK | University for Development Studies School of Medicine and Health Sciences Tamale Teaching Hospital | phase 3 | 6400 | April 25, 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10981 | |||||||||||||||||||||
44 | Guinea Bissau | OPV as Potential Protection Against COVID | Biological: oral polio vaccine + information|Behavioral: Information | Bandim Health Project | Phase 4 | 3400 | 1-Jul-2020 | https://ClinicalTrials.gov/show/NCT04445428 | |||||||||||||||||||||
45 | Guinea Bissau | CANCOVID-19 Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients | Combination Product: Hydroxycloroquine and Azythromycine Combination Product: Cospherunate/Azythromycine Combination Product: Cospherunate/Phytomedicine/Azythromycien | Institute for Research and Development of Medicinal and Food Plants of Guinea | Phase 2 | 30 | 20-July-2020 | https://ClinicalTrials.gov/show/NCT04502342 | |||||||||||||||||||||
46 | Guinea Bissau | Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention | Other: Certified cloth face mask plus preventive information|Behavioral: Preventive information | Bandim Health Project|University of Southern Denmark|Engineers without Borders, Denmark (https://iug.dk/en) | Not Applicable | 66000 | 20-July-2020 | https://ClinicalTrials.gov/show/NCT04471766 | |||||||||||||||||||||
47 | Guinea Conakry | PHYTCOVID-19 Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients | Combination Product: Hydroxychloroquine/Azithromycine Combination Product: Quinquina-Stevia/Azythromycin Combination Product: 4Plants/Azythromycin | Institute for Research and Development of Medicinal and Food Plants of Guinea | Phase 2 | 231 | June 2020 | https://ClinicalTrials.gov/show/NCT04501965 | |||||||||||||||||||||
48 | Ivory Coast | INTENSE-COV Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial | Drug: Lopinavir/Ritonavir Drug: Telmisartan Drug: Atorvastatin | Inserm-ANRS Programme PACCI | Phase 2|Phase 3 | 294 | 31-May-2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10988 | |||||||||||||||||||||
49 | Kenya | A study to determine if a new COVID-19 vaccine safely generates protective immune responses in adults in Kenya | Single dose of ChAdOx1 nCoV-19 vaccine 5x10^10 vp 0.5 mL of Verorab (rabies vaccine) via the intramuscular route. Single dose | University of Oxford | Phase 1 | 400 | 14-May-2020 | https://ClinicalTrials.gov/show/NCT04372186 | |||||||||||||||||||||
50 | Kenya | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | Drug: Placebo Drug: Tocilizumab | Genentech, Inc. | Phase 3 | 379 | 29-April-2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11103 | |||||||||||||||||||||
51 | Kenya | Western Kenya Integrated COVID 19 Response | Other: Training of youth, community health assistants and community health workers.| Other: Training clinicians in basic critical care and the management of severe COVID-19 cases | Surgical Systems Research Group|Wellcome Trust|Tropical Institute of Community Health | Not Applicable | 200000 | May 18, 2020 | https://ClinicalTrials.gov/show/NCT04501458 | |||||||||||||||||||||
52 | Kenya | A clinical trial comparing use of convalescent plasma therapy plus standard treatment to standard treatmentalone in patients with severe COVID-19 infection | Plasma based therapy | Kenyatta University Teaching Referral and Research Hospital | Phase 3 | 206 | Aug 1, 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11047 | |||||||||||||||||||||
53 | Madagascar | Efficacy of a new COVID-19 treatment | Drug: Artesunate IV Drug: Artesunate IV plus Vit C IV Other: Isotonic Saline Serum | Malagasy government | Phase 2 | 60 | June 1, 2020 | https://ClinicalTrials.gov/show/NCT04409483 | |||||||||||||||||||||
54 | Niger | TRASCOV Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger | Drug: Lopinavir-Ritonavir Drug Combination Combination Product: Standard Care | Epicentre Université Abdou Moumouni Centre de Recherche Médicale et Sanitaire Ministry of Public Health, Republic of Niger | Phase 3 | 928 | 17-April-2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928 | |||||||||||||||||||||
55 | Nigeria | LACCTT Lagos COVID-19 Chloroquine Treatment Trial | Drug : Chloroquine phosphate Drug : Hydroxychloroquine sulphate | Lagos State Governement Nigerian Institute of Medical Research | Not Applicable | 600 | 23-April-2020 | https://doi.org/10.1186/ISRCTN40302986 | |||||||||||||||||||||
56 | Nigeria | IVERCOVID Does ivermectin cure and/or prevent COVID-19? | Drug: ivermectin 6 mg Drug: ivermectin 12 mg Drug: placebo | Lagos University Teaching Hospital | Phase 3 | 45 | April 2020 | https://clinicaltrials.gov/ct2/show/NCT04343001?type=Intr&cond=covid&map_cntry=NG&draw=2&rank=1 | |||||||||||||||||||||
57 | Nigeria University College Hospital, Ibadan, Oyo, | CRASH-19 Coronavirus Response - Active Support for Hospitalised Covid-19 Patients | Drug: Aspirin Drug: Losartan Drug: Simvastatin | London School of Hygiene and Tropical Medicine | Phase 3 | 10000 | August 2020 | https://ClinicalTrials.gov/show/NCT04459286 | |||||||||||||||||||||
58 | Nigeria | NACOVID The Nitazoxanide Plus Atazanavir for COVID-19 Study | Drug: Nitazoxanide and atazanavir/ritonavir Other: Standard of Care | Obafemi Awolowo University University of Liverpool African Centre of Excellence for Genomics of Infectious Diseases Oyo State Ministry of Health | Phase 2 | 98 | August 2020 | https://ClinicalTrials.gov/show/NCT04466657 | |||||||||||||||||||||
59 | Nigeria | GSHSOD-COVID Antioxidant Therapy for COVID-19 Study | Dietary Supplement: Antioxidation Therapy Other: Standard of Care | Obafemi Awolowo University Borno State Ministry of Health Ogun State Ministry of Health Abia State Ministry of Health Sokoto State Ministry of Health Benue State Minsitry of Health University of Calabar Teaching Hospital | Not Applicable | 90 | 1-May-2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10957 | |||||||||||||||||||||
60 | Nigeria | IHP Detox tea trial Efficacy and safety of IHP Detox Tea for treatment of Corona virus disease 2019: a pilot placebo-controlled randomized trial | IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) | Neimeth International Pharmaceuticals Plc | Not Applicable | 72 | 1-Jun-2020 | https://ClinicalTrials.gov/show/NCT04442152 | |||||||||||||||||||||
61 | Nigeria | LACCPT Lagos Covid-19 Convalescent Plasma Trial | Plasma based therapy Other: Standard of Care | Lagos State Government | Phase 3 | 100 | 1-August-2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12168 | |||||||||||||||||||||
62 | Nigeria | LACBSOT Lagos COVID-19 Black Seed Oil Trial | Alternative therapy: Black seed oil Drug:LopinavirRitonavir Other: Standard of Care | Lagos State Government | Not Available | 80 | 1-September-2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12192 | |||||||||||||||||||||
63 | Nigeria | Effect of Interferential Therapy on SARS-CoV-2. COVID-19 | Other + Alternative therapy Other + Alternative therapy + Corticosteroids | Awolola Eniola Oladejo | Not Available | 48 | October 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11088 | |||||||||||||||||||||
64 | Rwanda | Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants | Behavioral: MenCare+/Bandebereho fathers'/couples' group education | Promundo, United States|Rwanda Men's Resource Center (Rwamrec)|Ministry of Health/Rwanda Biomedical Center | Not Applicable | 1000 | 1-Jun-2020 | https://ClinicalTrials.gov/show/NCT04390594 | |||||||||||||||||||||
65 | Senegal | SEN-CoV-Fadj Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal | Drug: Hydroxychloroquine Drug: Hydroxychloroquine + Azithromycin | Institut Pasteur de Dakar Fann Hospital, Senegal Ministry of Health, Senegal Diamniadio Children Hospital, Senegal Dalal Jamm Hospital, Senegal Epicentre, Paris, France | Phase 3 | 258 | Jun 1, 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11053 | |||||||||||||||||||||
66 | Senegal | ESHAZ Trial Hydroxychloroquine, Azithromycine and Zinc for the treatment of SARS-Cov2 infection in Senegal. COVID-19 | Drug: Hydrochloroquine 600 mg plus Azythromycine Drug: Hydrochloroquine 400 mg plus Azythromycine Drug: Zinc | Faculty of Medicine University Cheikh Anta Diop of Dakar Senegal. | Phase 3 | 384 | June 1, 2020 | https://ClinicalTrials.gov/show/NCT04381871 https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11053 | |||||||||||||||||||||
67 | Soudan | GA&COVID19 Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients | Dietary Supplement: Acacia Senegal Dietary Supplement: Pectin | Al-Neelain University University of Khartoum | Phase 2 Phase 3 | 110 | May 1, 2020 | https://ClinicalTrials.gov/show/NCT04360759 | |||||||||||||||||||||
68 | South Africa | CQOTE Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19 | Drug: Chloroquine or hydroxychloroquine | University of Cape Town | Phase 3 | 560 | May 4,2020 | Withdrawn (Equipoise for hydroxychloquine was lost) | https://ClinicalTrials.gov/show/NCT04379336 | ||||||||||||||||||||
69 | South Africa | BCG Vaccination for Healthcare Workers in COVID-19 Pandemic | Biological: Bacille Calmette-Guerin (BCG) Other: Placebo Comparator | TASK Applied Science (University of Cape Town) | Phase 3 | 500 | June 1,2020 | https://ClinicalTrials.gov/show/NCT04444674 | |||||||||||||||||||||
70 | South Africa | COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection | Biological: ChAdOx1 nCoV-19|Biological: Normal saline 0.9% | University of Witwatersrand, South Africa|Medical Research Council, South Africa|Bill and Melinda Gates Foundation|University of Oxford | Phase 1|Phase 2 | 2000 | May 2020 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/ | |||||||||||||||||||||
71 | South Africa | CALAVI A Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 | Drug: Acalabrutinib Other: Standard of care | Acerta Pharma B.V. | Phase 2 | 140 | Jun 1, 2020 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/ | |||||||||||||||||||||
72 | South Africa | OSCAR Investigating otilimab in patients with severe coronavirus related lung disease. | Drug: otilimab IV Other: Standard of care | GSK | Phase 2 | 800 | April 15, 2020 | https://clinicaltrials.gov/ct2/show/NCT04349228?type=Intr&cond=covid&map_cntry=TN&draw=2&rank=1 | |||||||||||||||||||||
73 | South Africa | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | Drug: Placebo|Drug: Tocilizumab | Genentech, Inc. | Phase 3 | 379 | May 14, 2020 | https://ClinicalTrials.gov/show/NCT04372186 | |||||||||||||||||||||
74 | South Africa | ENSEMBLE A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | Biological: Ad26.COV2.S|Other: Placebo | Janssen Vaccines & Prevention B.V. | Phase 3 | 60000 | September 5, 2020 | https://ClinicalTrials.gov/show/NCT04505722 | |||||||||||||||||||||
75 | South Africa | CALAVI A Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 | Drug: Acalabrutinib Other: Standard of care | Acerta Pharma B.V. | Phase 2 | 140 | May 13, 2020 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/ | |||||||||||||||||||||
76 | South Africa | TOGETHER 3 An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults | Drug:Lopinavir ritonavir Other: ascorbic acid | Cytel Inc | Not available | 420 | July 13, 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12194 | |||||||||||||||||||||
77 | South Africa | TRACE Transmission of Covid-19 in Crowded Environments | STOPCOV intervention Enhanced usual care | Desmond Tutu Health Foundation | 720 | August 3, 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12214 | ||||||||||||||||||||||
78 | Tunisia | COVID_2Pro Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals | Drug: Hydroxychloroquine (HCQ) Drug: Placebo oral tablet | Abderrahmane Mami Hospital Eshmoun Clinical Research Centre | Phase 3 | 530 | Apr 15, 2020 | https://clinicaltrials.gov/ct2/show/NCT04351919?type=Intr&cond=covid&map_cntry=TN&draw=2&rank=2 | |||||||||||||||||||||
79 | Tunisia | COVID+PA Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+) | Drug: Hydroxychloroquine Drug: Azithromycin | Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre | Phase 4 | 400 | May 4,2020 | https://ClinicalTrials.gov/show/NCT04361032 | |||||||||||||||||||||
80 | Tunisia | TRONCHER Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia | Drug: Tocilizumab Injection Drug: Deferoxamine | Abderrahmane Mami Hospital Eshmoun Clinical Research Centre Datametrix | Phase 3 | 260 | May 4,2020 | https://ClinicalTrials.gov/show/NCT04377646 | |||||||||||||||||||||
81 | Tunisia | COVID-Milit A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers | Drug: Hydroxychloroquine Drug: Hydroxychloroquine (placebo) Drug: Zinc|Drug: Zinc (Placebo) | Military Hospital of Tunis UR17DN02 : Autoimmune Diseases Research Unit Dacima Consulting | Phase 3 | 660 | May 2020 | https://ClinicalTrials.gov/show/NCT04361318 | |||||||||||||||||||||
82 | Tunisia | Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 | Combination Product: Hydroxychloroquine plus Nitazoxanide|Other: Standard care | Tanta University | Phase 2|Phase 3 | 100 | Apr 1, 2020 | https://clinicaltrials.gov/ct2/show/NCT04333732?type=Intr&cond=covid&map_cntry=ZM&draw=2&rank=1 https://doi.org/10.1186/ISRCTN99916292 | |||||||||||||||||||||
83 | Cameroon, Ghana Guinea Bissau, Uganda, South Africa, Zambia, Zimbabwe | CROWN CORONATION COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION | Drug: Low-dose chloroquine|Drug: Mid-dose chloroquine|Drug: High-dose chloroquine|Drug: Placebo Drug: MR or M-M-R II ® vaccine Drug: Placebo | Washington University School of Medicine|Bill and Melinda Gates Foundation|COVID -19 Therapeutics Accelerator | Phase 3 | 30000 | June 1, 2020 | https://ClinicalTrials.gov/show/NCT04333732 http://www.isrctn.com/ISRCTN99916292 | |||||||||||||||||||||
84 | Kenya, South Africa | SOLIDARITY Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients | 1. Local standard of care alone OR local standard of care plus one of 2. Remdesivir 3. Chloroquine or hydroxychloroquine 4. Lopinavir + ritonavir 5. Lopinavir + ritonavir plus interferon-beta | WHO | Phase 3 | 10000 | March 3, 2020 | https://doi.org/10.1186/ISRCTN83971151 | |||||||||||||||||||||
85 | Benin, Ghana, Nigeria, Rwanda, South Africa | PROTECT-Surg Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 | Drug: Lopinavir-Ritonavir|Drug: Hydroxychloroquine | University of Birmingham|Christian Medical College and Hospital, Ludhiana, India|Tamale Teaching Hospital, Ghana.|University of Lagos, Nigeria|Kigali University Teaching Hospital|Hospital Espagnol Veracruz|Université d'Abomey-Calavi|University of Witwatersrand, South Africa|University of Edinburgh|Istituto Clinico Humanitas|University of Cape Town | Phase 3 | 6400 | May 15, 2020 | https://ClinicalTrials.gov/show/NCT04386070 | |||||||||||||||||||||
86 | Burkina Faso, Cameroon, Cote D'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Mozambique, Sudan, Tanzania, Uganda | ANTICOV An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19 | Drug: HCQ, LPV/r Other: Standard of Care (paracetamol) | Epicentre, DNDI, ANRS, Institut Pasteur Cameroon, Ifakara Health Institute, ISGlobal, ITM, Bernhard Nocht Institute for Tropical Medicine | Not Applicable | 3000 | July 20, 2020 | https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150 | |||||||||||||||||||||
87 | |||||||||||||||||||||||||||||
88 | |||||||||||||||||||||||||||||
89 | |||||||||||||||||||||||||||||
90 | |||||||||||||||||||||||||||||
91 | |||||||||||||||||||||||||||||
92 | |||||||||||||||||||||||||||||
93 | |||||||||||||||||||||||||||||
94 | |||||||||||||||||||||||||||||
95 | |||||||||||||||||||||||||||||
96 | |||||||||||||||||||||||||||||
97 | |||||||||||||||||||||||||||||
98 | |||||||||||||||||||||||||||||
99 | |||||||||||||||||||||||||||||
100 |